Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMF5794)

Drug Name
URO-902 Drug Info
Indication
Disease Entry ICD 11 Status REF
Overactive bladder GC50.0 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMF5794

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcium-activated potassium channel KCa1.1 (KCNMA1) TTE87WJ KCMA1_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Calcium-activated potassium channel KCa1.1 (KCNMA1) DTT KCNMA1 4.492 4.828 4.973 4.426
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Overactive bladder
ICD Disease Classification GC50.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Calcium-activated potassium channel KCa1.1 (KCNMA1) DTT KCNMA1 4.48E-03 0.19 0.7
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04211831) An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence. U.S.National Institutes of Health.
2 Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials. Neurourol Urodyn. 2020 Feb;39(2):744-753.